IGF1R and lymphoma: The results here also find chemosensitivity in NCI60 tumor cell lines having defective PIK3R1. The second example of defective IGF1R supports the importance of evaluating drug sensitivity for compounds targeting leukemia cell lines [26] and the emergence of IGF1R as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma [27].